ES537325A0 - Un metodo de producir una microcapsula de liberacion prolongada de un farmaco soluble en agua - Google Patents

Un metodo de producir una microcapsula de liberacion prolongada de un farmaco soluble en agua

Info

Publication number
ES537325A0
ES537325A0 ES537325A ES537325A ES537325A0 ES 537325 A0 ES537325 A0 ES 537325A0 ES 537325 A ES537325 A ES 537325A ES 537325 A ES537325 A ES 537325A ES 537325 A0 ES537325 A0 ES 537325A0
Authority
ES
Spain
Prior art keywords
microcapsula
release
producing
long
water
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES537325A
Other languages
English (en)
Other versions
ES8605983A1 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=16545089&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES537325(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of ES537325A0 publication Critical patent/ES537325A0/es
Publication of ES8605983A1 publication Critical patent/ES8605983A1/es
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
    • B01J13/02—Making microcapsules or microballoons
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
    • B01J13/02—Making microcapsules or microballoons
    • B01J13/06—Making microcapsules or microballoons by phase separation
    • B01J13/12—Making microcapsules or microballoons by phase separation removing solvent from the wall-forming material solution
    • B01J13/125—Making microcapsules or microballoons by phase separation removing solvent from the wall-forming material solution by evaporation of the solvent
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/15—Suppositories
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
    • Y10T428/2984—Microcapsule with fluid core [includes liposome]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
    • Y10T428/2984—Microcapsule with fluid core [includes liposome]
    • Y10T428/2985—Solid-walled microcapsule from synthetic polymer
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
    • Y10T428/2989—Microcapsule with solid core [includes liposome]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
ES537325A 1983-11-04 1984-11-02 Un metodo de producir una microcapsula de liberacion prolongada de un farmaco soluble en agua Expired ES8605983A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP58207760A JPS60100516A (ja) 1983-11-04 1983-11-04 徐放型マイクロカプセルの製造法

Publications (2)

Publication Number Publication Date
ES537325A0 true ES537325A0 (es) 1986-04-01
ES8605983A1 ES8605983A1 (es) 1986-04-01

Family

ID=16545089

Family Applications (1)

Application Number Title Priority Date Filing Date
ES537325A Expired ES8605983A1 (es) 1983-11-04 1984-11-02 Un metodo de producir una microcapsula de liberacion prolongada de un farmaco soluble en agua

Country Status (13)

Country Link
US (7) US4652441A (es)
EP (1) EP0145240B1 (es)
JP (1) JPS60100516A (es)
BG (1) BG60493B2 (es)
CA (1) CA1233414A (es)
DE (1) DE3477732D1 (es)
ES (1) ES8605983A1 (es)
GR (1) GR80818B (es)
HK (1) HK3792A (es)
HU (1) HU193910B (es)
IE (1) IE57721B1 (es)
PT (1) PT79450B (es)
SG (1) SG103491G (es)

Families Citing this family (569)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8514090D0 (en) * 1985-06-04 1985-07-10 Sandoz Ltd Organic compounds
JPS60100516A (ja) * 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
EP0190833B1 (en) * 1985-02-07 1991-03-27 Takeda Chemical Industries, Ltd. Method for producing microcapsule
JP2551756B2 (ja) * 1985-05-07 1996-11-06 武田薬品工業株式会社 ポリオキシカルボン酸エステルおよびその製造法
US4734399A (en) * 1985-08-06 1988-03-29 Hoffmann-La Roche Inc. Growth hormone releasing factor analogs
US5112619A (en) * 1985-11-12 1992-05-12 Eli Lilly And Company Orally administerable sustained release pharmaceutical formulation
ES2039203T3 (es) * 1985-11-22 1993-09-16 Takeda Chemical Industries, Ltd. Composicion de liposomas.
CA1275922C (en) * 1985-11-28 1990-11-06 Harunobu Amagase Treatment of cancer
US4780320A (en) * 1986-04-29 1988-10-25 Pharmetrix Corp. Controlled release drug delivery system for the periodontal pocket
US4832686A (en) * 1986-06-24 1989-05-23 Anderson Mark E Method for administering interleukin-2
JPS6341416A (ja) * 1986-08-08 1988-02-22 Takeda Chem Ind Ltd 鎮痛性ペプチド含有マイクロカプセルの製造法
JP2526589B2 (ja) * 1986-08-08 1996-08-21 武田薬品工業株式会社 ペプチド含有マイクロカプセルおよびその製造法
JPH0725689B2 (ja) * 1986-10-07 1995-03-22 中外製薬株式会社 顆粒球コロニ−刺激因子を含有する徐放性製剤
CA1321048C (en) * 1987-03-05 1993-08-10 Robert W. J. Lencki Microspheres and method of producing same
US4857335A (en) * 1987-03-27 1989-08-15 Lim Technology Laboratories, Inc. Liquid controlled release formulations and method of producing same via multiple emulsion process
US5500228A (en) * 1987-05-26 1996-03-19 American Cyanamid Company Phase separation-microencapsulated pharmaceuticals compositions useful for alleviating dental disease
US5143661A (en) * 1987-05-26 1992-09-01 American Cyanamid Company Silicone-hardened pharmaceutical microcapsules
US4880632A (en) * 1987-09-08 1989-11-14 The United States Of America Prevention of fescue toxicosis
GB2209937B (en) * 1987-09-21 1991-07-03 Depiopharm S A Water insoluble polypeptides
JPH0725649B2 (ja) * 1987-10-12 1995-03-22 而至歯科工業株式会社 消毒剤含有アルギン酸印象材
US5187150A (en) * 1987-10-14 1993-02-16 Debiopharm S.A. Polyester-based composition for the controlled release of polypeptide medicinal substances
WO1989003678A1 (en) * 1987-10-30 1989-05-05 Stolle Research & Development Corporation Low residual solvent microspheres and microencapsulation process
US5051261A (en) * 1987-11-24 1991-09-24 Fmc Corporation Method for preparing a solid sustained release form of a functionally active composition
US5290562A (en) * 1987-11-27 1994-03-01 L V M H Recherche Compositions and methods employing liposomes including tyrosine or a tyrosine derivative
EP0326151B1 (en) * 1988-01-29 1993-06-16 Sumitomo Pharmaceuticals Company, Limited Improved controlled release formulation
JP2670680B2 (ja) * 1988-02-24 1997-10-29 株式会社ビーエムジー 生理活性物質含有ポリ乳酸系微小球およびその製造法
US4952408A (en) * 1988-05-23 1990-08-28 Georgetown University Liposome-encapsulated vinca alkaloids and their use in combatting tumors
US5271945A (en) * 1988-07-05 1993-12-21 Takeda Chemical Industries, Ltd. Sustained release microcapsule for water soluble drug
US5298255A (en) * 1988-10-28 1994-03-29 Terumo Kabushiki Kaisha Antithrombic medical material, artificial internal organ, and method for production of antithrombic medical material
ES2051968T3 (es) * 1988-12-22 1994-07-01 American Cyanamid Co Metodo para el tratamiento de enfermedad periodontal mediante la liberacion continua de un agente terapeutico a la bolsa periodontal; composicion de materia del mismo y aparato para su administracion.
US5236355A (en) * 1988-12-22 1993-08-17 American Cyanamid Company Apparatus for the treatment of periodontal disease
US5051305A (en) * 1988-12-30 1991-09-24 Arcade, Inc. Stabilized perfume-containing microcapsules and method of preparing the same
ES2084698T5 (es) * 1989-05-04 2005-03-01 Southern Research Institute Procedimiento de encapsulacion.
IT8920486A0 (it) * 1989-05-12 1989-05-12 Isf Spa Composizioni farmaceutiche.
HU221294B1 (en) * 1989-07-07 2002-09-28 Novartis Ag Process for producing retarde compositions containing the active ingredient in a polymeric carrier
PH30995A (en) * 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
WO1991006287A1 (en) * 1989-11-06 1991-05-16 Enzytech, Inc. Protein microspheres and methods of using them
FR2654337B1 (fr) * 1989-11-15 1994-08-05 Roussel Uclaf Nouvelles microspheres injectables biodegradables procede de preparation et suspensions injectables les renfermant.
US5198220A (en) * 1989-11-17 1993-03-30 The Procter & Gamble Company Sustained release compositions for treating periodontal disease
JP2958103B2 (ja) * 1989-12-12 1999-10-06 エーザイ株式会社 プラズマ照射固形製剤
JP2653255B2 (ja) * 1990-02-13 1997-09-17 武田薬品工業株式会社 長期徐放型マイクロカプセル
MY107937A (en) * 1990-02-13 1996-06-29 Takeda Chemical Industries Ltd Prolonged release microcapsules.
US5478564A (en) * 1990-02-22 1995-12-26 Teva Pharmaceutical Industries, Ltd. Preparation of microparticles for controlled release of water-soluble substances
EP0452111B1 (en) * 1990-04-13 1998-07-15 Takeda Chemical Industries, Ltd. Biodegradable high-molecular polymers, production and use thereof
US6517859B1 (en) 1990-05-16 2003-02-11 Southern Research Institute Microcapsules for administration of neuroactive agents
EP0528978B1 (en) * 1990-05-16 2002-10-16 Southern Research Institute Mikrocaspules for controlled release and their use to stimulate nerve fiber growth
JP3116311B2 (ja) * 1990-06-13 2000-12-11 エーザイ株式会社 マイクロスフィアの製法
US5364839A (en) * 1990-06-18 1994-11-15 Genetics Institute, Inc. Osteoinductive pharmaceutical formulations
GB9016885D0 (en) * 1990-08-01 1990-09-12 Scras Sustained release pharmaceutical compositions
US5418010A (en) * 1990-10-05 1995-05-23 Griffith Laboratories Worldwide, Inc. Microencapsulation process
KR930006431B1 (ko) * 1990-10-11 1993-07-16 재단법인 한국화학연구소 약물의 미세캡슐화 방법
ZA918168B (en) 1990-10-16 1993-04-14 Takeda Chemical Industries Ltd Prolonged release preparation and polymers thereof.
US5206023A (en) * 1991-01-31 1993-04-27 Robert F. Shaw Method and compositions for the treatment and repair of defects or lesions in cartilage
US5378475A (en) * 1991-02-21 1995-01-03 University Of Kentucky Research Foundation Sustained release drug delivery devices
US5654009A (en) * 1991-03-25 1997-08-05 Fujisawa Pharmaceutical Co., Ltd. Delayed action preparation
JPH04364131A (ja) * 1991-04-03 1992-12-16 Sanwa Kagaku Kenkyusho Co Ltd 易吸収性モチリン製剤
JP3351525B2 (ja) * 1991-06-21 2002-11-25 ジェネティックス・インスティテュート・インコーポレイテッド 骨形成性蛋白医薬処方物
US5252337A (en) * 1991-06-25 1993-10-12 Eurand America, Inc. Controlled release calcium channel blocker microcapsules
CH683149A5 (fr) * 1991-07-22 1994-01-31 Debio Rech Pharma Sa Procédé pour la préparation de microsphères en matériau polymère biodégradable.
US5270300A (en) * 1991-09-06 1993-12-14 Robert Francis Shaw Methods and compositions for the treatment and repair of defects or lesions in cartilage or bone
DE69220317T2 (de) * 1991-10-01 1997-10-16 Takeda Chemical Industries Ltd Mikropartikeln-Zusammenfassung zur verlängerten Freigabe und Herstellung derselbe
US5288502A (en) * 1991-10-16 1994-02-22 The University Of Texas System Preparation and uses of multi-phase microspheres
CA2121129A1 (en) * 1991-10-29 1993-05-13 Patrick Soon-Shiong Crosslinkable polysaccharides, polycations and lipids useful for encapsulation and drug release
DK0617612T3 (da) * 1991-12-18 1998-04-14 Warner Lambert Co Fremgangsmåde til fremstilling af en fast dispersion
US5470582A (en) * 1992-02-07 1995-11-28 Syntex (U.S.A.) Inc. Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles
US5912015A (en) * 1992-03-12 1999-06-15 Alkermes Controlled Therapeutics, Inc. Modulated release from biocompatible polymers
DE69318835T2 (de) * 1992-04-06 1998-11-05 Uroplasty, Inc., Minneapolis, Minn. Behandlung einer refluxstörung durch injektion von mikropartikeln
US5922652A (en) * 1992-05-05 1999-07-13 Procter & Gamble Microencapsulated oil field chemicals
US5674534A (en) * 1992-06-11 1997-10-07 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US20030035845A1 (en) * 1992-06-11 2003-02-20 Zale Stephen E. Composition for sustained release of non-aggregated erythropoietin
US5716644A (en) * 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
JP2651320B2 (ja) * 1992-07-16 1997-09-10 田辺製薬株式会社 徐放性マイクロスフェア製剤の製造方法
AU4198793A (en) * 1992-07-24 1994-01-27 Takeda Chemical Industries Ltd. Microparticle preparation and production thereof
FR2693905B1 (fr) * 1992-07-27 1994-09-02 Rhone Merieux Procédé de préparation de microsphères pour la libération prolongée de l'hormone LHRH et ses analogues, microsphères et formulations obtenues.
DE69316101T2 (de) * 1992-08-07 1998-10-22 Takeda Chemical Industries Ltd Herstellung von Mikrokapseln, die wasserlösliche Arzneimittel enthalten
JP3277342B2 (ja) * 1992-09-02 2002-04-22 武田薬品工業株式会社 徐放性マイクロカプセルの製造法
EP1132080A3 (en) * 1992-09-10 2001-10-17 Children's Medical Center Corporation Biodegradable polymer matrices for sustained delivery of local anesthetic agents
US5922340A (en) * 1992-09-10 1999-07-13 Children's Medical Center Corporation High load formulations and methods for providing prolonged local anesthesia
US5700485A (en) * 1992-09-10 1997-12-23 Children's Medical Center Corporation Prolonged nerve blockade by the combination of local anesthetic and glucocorticoid
DE4231493A1 (de) * 1992-09-21 1994-03-24 Nordmark Arzneimittel Gmbh Verfahren zur Herstellung von Pellets aus einem Ephedrinderivat
EP0595030A3 (en) * 1992-10-01 1995-06-07 Tanabe Seiyaku Co Multi-core microspheres with delayed drug delivery and process for their manufacture.
US5242910A (en) * 1992-10-13 1993-09-07 The Procter & Gamble Company Sustained release compositions for treating periodontal disease
US5310742A (en) * 1992-11-30 1994-05-10 Elias Alan N Uses for thioureylenes
TW333456B (en) 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
JPH06239746A (ja) * 1993-02-12 1994-08-30 Mayumi Okada モルヒネ徐放性製剤
JP3698721B2 (ja) * 1993-02-23 2005-09-21 ジェネンテク・インコーポレイテッド 有機溶媒を用いて処理したポリペプチドの賦形剤安定化
US5981719A (en) 1993-03-09 1999-11-09 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
US6090925A (en) 1993-03-09 2000-07-18 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
ES2070076B1 (es) * 1993-04-20 1996-04-16 Cusi Lab Metodo para aumentar la estabilidad de las nanocapsulas durante su almacenamiento.
US5447725A (en) * 1993-06-11 1995-09-05 The Procter & Gamble Company Methods for aiding periodontal tissue regeneration
US5449663A (en) * 1993-06-11 1995-09-12 Bicher; Haim I. Antineoplastic compositions
US5643605A (en) * 1993-10-25 1997-07-01 Genentech, Inc. Methods and compositions for microencapsulation of adjuvants
US6080429A (en) * 1993-10-25 2000-06-27 Genentech, Inc. Method for drying microspheres
US6913767B1 (en) 1993-10-25 2005-07-05 Genentech, Inc. Compositions for microencapsulation of antigens for use as vaccines
AU693821B2 (en) * 1993-11-18 1998-07-09 Sirtex Medical Limited Controlled release preparation
US5474985A (en) * 1993-12-22 1995-12-12 The Regents Of The University Of California Preventing and treating elevated intraocular pressure associated with administered or endogenous steroids using non-steroidal cyclooxygenase inhibitors
US5594091A (en) * 1994-02-21 1997-01-14 Takeda Chemical Industries, Ltd. Matrix for sustained-release preparation
IE940292A1 (en) * 1994-04-06 1995-10-18 Elan Corp Plc Biodegradable microcapsules and method for their manufacture
US5538733A (en) * 1994-07-07 1996-07-23 Willmar Poultry Company, Inc. Method of priming an immune response in a one-day old animal
CA2150060C (en) * 1994-07-08 2000-01-11 John T. Biggs Seamless multimedia conferencing system using enhanced endpoint devices
US5626862A (en) 1994-08-02 1997-05-06 Massachusetts Institute Of Technology Controlled local delivery of chemotherapeutic agents for treating solid tumors
US5520923A (en) * 1994-09-19 1996-05-28 Genetics Institute, Inc. Formulations for delivery of osteogenic proteins
US5538737A (en) * 1994-11-30 1996-07-23 Applied Analytical Industries, Inc. Oral compositions of H2 -antagonists
DE4443175A1 (de) * 1994-12-05 1996-06-13 Jenapharm Gmbh Neue pulsatile Arzneiform
US5674888A (en) * 1995-06-07 1997-10-07 University Of California Method for the treatment of a trabecular meshwork whose cells are subject to inhibition of cell division
US5879712A (en) * 1995-06-07 1999-03-09 Sri International Method for producing drug-loaded microparticles and an ICAM-1 dosage form so produced
US5599535A (en) * 1995-06-07 1997-02-04 Regents Of The University Of California Methods for the cyto-protection of the trabecular meshwork
HUP9700322A3 (en) 1995-06-09 2001-03-28 Euro Celtique Sa Formulations and methods for providing prolonged local anesthesia
AU710347B2 (en) * 1995-08-31 1999-09-16 Alkermes Controlled Therapeutics, Inc. Composition for sustained release of an agent
TW448055B (en) * 1995-09-04 2001-08-01 Takeda Chemical Industries Ltd Method of production of sustained-release preparation
US5702717A (en) * 1995-10-25 1997-12-30 Macromed, Inc. Thermosensitive biodegradable polymers based on poly(ether-ester)block copolymers
US5665428A (en) * 1995-10-25 1997-09-09 Macromed, Inc. Preparation of peptide containing biodegradable microspheres by melt process
WO1997017063A1 (en) 1995-11-09 1997-05-15 Microbiological Research Authority Microencapsulated dna for vaccination and gene therapy
US6270795B1 (en) 1995-11-09 2001-08-07 Microbiological Research Authority Method of making microencapsulated DNA for vaccination and gene therapy
DE19545257A1 (de) 1995-11-24 1997-06-19 Schering Ag Verfahren zur Herstellung von morphologisch einheitlichen Mikrokapseln sowie nach diesem Verfahren hergestellte Mikrokapseln
CA2192773C (en) 1995-12-15 2008-09-23 Hiroaki Okada Production of sustained-release preparation for injection
CA2192782C (en) 1995-12-15 2008-10-14 Nobuyuki Takechi Production of microspheres
US5747060A (en) * 1996-03-26 1998-05-05 Euro-Celtique, S.A. Prolonged local anesthesia with colchicine
WO1997049391A1 (en) 1996-06-24 1997-12-31 Euro-Celtique, S.A. Methods for providing safe local anesthesia
US7871637B2 (en) 1996-08-27 2011-01-18 Baxter International Inc. Dry hemostatic compositions and methods for their preparation
US8603511B2 (en) 1996-08-27 2013-12-10 Baxter International, Inc. Fragmented polymeric compositions and methods for their use
US7435425B2 (en) * 2001-07-17 2008-10-14 Baxter International, Inc. Dry hemostatic compositions and methods for their preparation
US8303981B2 (en) 1996-08-27 2012-11-06 Baxter International Inc. Fragmented polymeric compositions and methods for their use
US6066325A (en) * 1996-08-27 2000-05-23 Fusion Medical Technologies, Inc. Fragmented polymeric compositions and methods for their use
US6419961B1 (en) 1996-08-29 2002-07-16 Takeda Chemical Industries, Ltd. Sustained release microcapsules of a bioactive substance and a biodegradable polymer
US6046187A (en) * 1996-09-16 2000-04-04 Children's Medical Center Corporation Formulations and methods for providing prolonged local anesthesia
ES2221019T3 (es) * 1996-10-31 2004-12-16 Takeda Chemical Industries, Ltd. Preparacion de liberacion mantenida.
US20020182258A1 (en) * 1997-01-22 2002-12-05 Zycos Inc., A Delaware Corporation Microparticles for delivery of nucleic acid
US5945126A (en) * 1997-02-13 1999-08-31 Oakwood Laboratories L.L.C. Continuous microsphere process
US7150881B2 (en) 1997-06-26 2006-12-19 Mylan Technologies, Inc. Adhesive mixture for transdermal delivery of highly plasticizing drugs
DE69821940T2 (de) 1997-06-30 2005-03-17 Monsanto Technology Llc Landwirtschaftlich aktive inhaltsstoffe enthaltende mikropartikel
BR9815499A (pt) 1997-07-02 2001-01-02 Euro Celtique Sa Anestesia prolongada nas juntas e nos espacos corporais.
US6391452B1 (en) * 1997-07-18 2002-05-21 Bayer Corporation Compositions for nasal drug delivery, methods of making same, and methods of removing residual solvent from pharmaceutical preparations
US5902598A (en) * 1997-08-28 1999-05-11 Control Delivery Systems, Inc. Sustained release drug delivery devices
ES2343767T3 (es) 1997-09-18 2010-08-09 Pacira Pharmaceuticals, Inc. Composiciones anestesicas liposomicas de liberacion sostenida.
US6117949A (en) * 1998-10-01 2000-09-12 Macromed, Inc. Biodegradable low molecular weight triblock poly (lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
US6004573A (en) * 1997-10-03 1999-12-21 Macromed, Inc. Biodegradable low molecular weight triblock poly(lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
US6201072B1 (en) 1997-10-03 2001-03-13 Macromed, Inc. Biodegradable low molecular weight triblock poly(lactide-co- glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
US6045835A (en) * 1997-10-08 2000-04-04 Givaudan Roure (International) Sa Method of encapsulating flavors and fragrances by controlled water transport into microcapsules
US6106875A (en) * 1997-10-08 2000-08-22 Givaudan Roure (International) Sa Method of encapsulating flavors and fragrances by controlled water transport into microcapsules
SE512663C2 (sv) * 1997-10-23 2000-04-17 Biogram Ab Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer
JP4234803B2 (ja) 1997-10-27 2009-03-04 久光製薬株式会社 薬物放出速度が制御された医薬組成物
TW577758B (en) 1997-10-27 2004-03-01 Ssp Co Ltd Intra-articular preparation for the treatment of arthropathy
JP4575592B2 (ja) * 1997-11-14 2010-11-04 パシラ ファーマシューティカルズ インコーポレーテッド 多小胞リポソームの製造
AU1982599A (en) 1998-01-21 1999-08-09 Takeda Chemical Industries Ltd. Lyophilization method for sustained-release preparations
US20030180368A1 (en) * 1998-03-14 2003-09-25 Cenes Drug Delivery Limited Production of microparticles
EP1063973B1 (en) 1998-03-19 2016-11-16 Bristol-Myers Squibb Company Biphasic controlled release delivery system for high solubility pharmaceuticals and method
US6099859A (en) * 1998-03-20 2000-08-08 Andrx Pharmaceuticals, Inc. Controlled release oral tablet having a unitary core
US7128927B1 (en) * 1998-04-14 2006-10-31 Qlt Usa, Inc. Emulsions for in-situ delivery systems
SE9801288D0 (sv) 1998-04-14 1998-04-14 Astra Ab Vaccine delivery system and metod of production
US6217844B1 (en) * 1998-04-27 2001-04-17 Praecis Pharmaceuticals, Inc. Methods for detecting lesions in dense breast tissue using LHRH antagonists
US7022683B1 (en) * 1998-05-13 2006-04-04 Carrington Laboratories, Inc. Pharmacological compositions comprising pectins having high molecular weights and low degrees of methoxylation
GB9810236D0 (en) 1998-05-13 1998-07-08 Microbiological Res Authority Improvements relating to encapsulation of bioactive agents
US6451335B1 (en) 1998-07-02 2002-09-17 Euro-Celtique S.A. Formulations and methods for providing prolonged local anesthesia
WO2000003660A1 (en) 1998-07-17 2000-01-27 Skyepharma, Inc. Biodegradable compositions for the controlled release of encapsulated substances
US20070009605A1 (en) * 1998-07-23 2007-01-11 Ignatious Francis X Encapsulation of water soluble peptides
US6200590B1 (en) 1998-08-10 2001-03-13 Naphcare, Inc. Controlled, phased-release suppository and its method of production
US7662409B2 (en) * 1998-09-25 2010-02-16 Gel-Del Technologies, Inc. Protein matrix materials, devices and methods of making and using thereof
US20050147690A1 (en) * 1998-09-25 2005-07-07 Masters David B. Biocompatible protein particles, particle devices and methods thereof
US6270802B1 (en) 1998-10-28 2001-08-07 Oakwood Laboratories L.L.C. Method and apparatus for formulating microspheres and microcapsules
US6565874B1 (en) * 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
US6204308B1 (en) 1999-03-01 2001-03-20 Novartis Ag Organic compounds
US20040121014A1 (en) * 1999-03-22 2004-06-24 Control Delivery Systems, Inc. Method for treating and/or preventing retinal diseases with sustained release corticosteroids
US6217895B1 (en) 1999-03-22 2001-04-17 Control Delivery Systems Method for treating and/or preventing retinal diseases with sustained release corticosteroids
US6287588B1 (en) * 1999-04-29 2001-09-11 Macromed, Inc. Agent delivering system comprised of microparticle and biodegradable gel with an improved releasing profile and methods of use thereof
US6709427B1 (en) 1999-08-05 2004-03-23 Kensey Nash Corporation Systems and methods for delivering agents into targeted tissue of a living being
AU6536400A (en) * 1999-08-11 2001-03-05 Alkermes Controlled Therapeutics, Inc. Method of delivering a chemotherapeutic agent to a solid tumor
KR100730440B1 (ko) * 1999-08-27 2007-06-19 브룩우드 파마슈티컬스, 인코포레이티드 주사가능한 부프레노르핀 미세 입자 조성물 및 이의 용도
US7582311B1 (en) 1999-10-15 2009-09-01 Genentech, Inc. Injection vehicle for polymer-based formulations
US7651703B2 (en) * 1999-10-15 2010-01-26 Genentech, Inc. Injection vehicle for polymer-based formulations
ATE271886T1 (de) 1999-10-15 2004-08-15 Inst Genetics Llc Hyaluronsäure enthaltende zusammensetzungen zur abgabe osteogener proteine
US6458387B1 (en) * 1999-10-18 2002-10-01 Epic Therapeutics, Inc. Sustained release microspheres
US6461631B1 (en) 1999-11-16 2002-10-08 Atrix Laboratories, Inc. Biodegradable polymer composition
US6682754B2 (en) 1999-11-24 2004-01-27 Willmar Poultry Company, Inc. Ovo delivery of an immunogen containing implant
US7771746B2 (en) * 1999-12-03 2010-08-10 Polichem Sa Methods for making sustained-release pharmaceutical compositions of ergot alkaloids having improved bioavailability and compositions thereof
ES2169980B1 (es) 1999-12-17 2003-11-01 Lipotec Sa Microcapsulas para la liberacion prolongada de farmacos.
CA2398466A1 (en) * 2000-01-27 2001-08-02 Medimmune, Inc. Ultra high affinity neutralizing antibodies
TW200800298A (en) 2000-01-27 2008-01-01 Zentaris Ag Compressed microparticles for dry injection
US6465425B1 (en) * 2000-02-10 2002-10-15 Alkermes Controlled Therapeutics, Inc. Microencapsulation and sustained release of biologically active acid-stable or free sulfhydryl-containing proteins
AU4002001A (en) 2000-03-01 2001-09-12 Med Immune Inc High potency recombinant antibodies and method for producing them
US7153525B1 (en) 2000-03-22 2006-12-26 The University Of Kentucky Research Foundation Microemulsions as precursors to solid nanoparticles
CN1438861A (zh) 2000-04-26 2003-08-27 沃特森药物公司 最小化与奥昔布宁疗法有关的副作用
US7029694B2 (en) 2000-04-26 2006-04-18 Watson Laboratories, Inc. Compositions and methods for transdermal oxybutynin therapy
US6375972B1 (en) 2000-04-26 2002-04-23 Control Delivery Systems, Inc. Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
US7179483B2 (en) * 2000-04-26 2007-02-20 Watson Pharmaceuticals, Inc. Compositions and methods for transdermal oxybutynin therapy
US20030124177A1 (en) * 2000-04-26 2003-07-03 Watson Pharmaceuticals, Inc. Compositions and methods for transdermal oxybutynin therapy
US7018645B1 (en) * 2000-04-27 2006-03-28 Macromed, Inc. Mixtures of various triblock polyester polyethylene glycol copolymers having improved gel properties
US6589549B2 (en) * 2000-04-27 2003-07-08 Macromed, Incorporated Bioactive agent delivering system comprised of microparticles within a biodegradable to improve release profiles
AR023940A1 (es) 2000-05-03 2002-09-04 Eriochem Sa Procedimiento para la produccion de microcapsulas de liberacion prolongada de peptidos solubles en agua
US6495164B1 (en) * 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
CN1141974C (zh) * 2000-06-07 2004-03-17 张昊 结肠定位释放的口服生物制剂
WO2002002144A1 (fr) 2000-07-05 2002-01-10 Takeda Chemical Industries, Ltd. Preparations medicinales pour le traitement des maladies dependant des hormones sexuelles
US7019106B2 (en) * 2000-08-07 2006-03-28 Wako Pure Chemical Industries, Ltd. Lactic acid polymer and process for producing the same
FR2814380B1 (fr) * 2000-09-25 2002-11-08 Serobiologiques Lab Sa Poudre de microcapsules et procede d'obtention
WO2002043580A2 (en) 2000-10-27 2002-06-06 Epic Therapeutics, Inc. Production of microspheres
US8470359B2 (en) * 2000-11-13 2013-06-25 Qlt Usa, Inc. Sustained release polymer
US6855493B2 (en) 2000-11-28 2005-02-15 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US7179900B2 (en) * 2000-11-28 2007-02-20 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US7252842B2 (en) 2000-12-21 2007-08-07 Alrise Biosystems Gmbh Induced phase transition method for the production of microparticles containing hydrophilic active agents
WO2002058670A1 (en) * 2001-01-25 2002-08-01 Euroceltique S.A. Local anesthetic, and method of use
US7494669B2 (en) * 2001-02-28 2009-02-24 Carrington Laboratories, Inc. Delivery of physiological agents with in-situ gels comprising anionic polysaccharides
US6777000B2 (en) * 2001-02-28 2004-08-17 Carrington Laboratories, Inc. In-situ gel formation of pectin
FR2822834B1 (fr) * 2001-04-02 2005-02-25 Flamel Tech Sa Suspension colloidale de nanoparticules a base de copolymeres amphiphile pour la vectorisation de principes actifs et leur mode de preparation
WO2002094320A1 (en) 2001-05-23 2002-11-28 Tanabe Seiyaku Co., Ltd. Therapeutic compositions for repairing chondropathy
WO2002094321A1 (en) 2001-05-23 2002-11-28 Tanabe Seiyaku Co., Ltd. Compositions for promoting healing of bone fracture
US20030096000A1 (en) * 2001-05-31 2003-05-22 Solis Rosa Maria Encapsulation of nanosuspensions in liposomes and microspheres
CA2451187C (en) 2001-06-22 2012-08-14 Southern Biosystems, Inc. Zero-order prolonged release coaxial implants
TWI225416B (en) 2001-06-29 2004-12-21 Takeda Chemical Industries Ltd Sustained-release composition and process for producing the same
TWI332407B (en) 2001-06-29 2010-11-01 Takeda Chemical Industries Ltd Controlled release composition and method of producting the same
US9820982B2 (en) 2001-07-06 2017-11-21 Endo Pharmaceuticals Inc. Oxymorphone controlled release formulations
US8329216B2 (en) 2001-07-06 2012-12-11 Endo Pharmaceuticals Inc. Oxymorphone controlled release formulations
BR0210855A (pt) * 2001-07-06 2006-10-24 Penwest Pharmaceuticals Compan Método de fabricação de formulações de liberação prolongada
CN1278675C (zh) 2001-07-10 2006-10-11 佳能株式会社 含聚羟基烷醇酸酯的粒状体及其制备方法
US20080026068A1 (en) * 2001-08-16 2008-01-31 Baxter Healthcare S.A. Pulmonary delivery of spherical insulin microparticles
EP1418890B1 (en) * 2001-08-16 2008-05-14 Baxter International Inc. Propellant-based microparticle formulations
ATE381963T1 (de) * 2001-10-26 2008-01-15 Octoplus Technologies B V Verfahren zur herstellung von gereinigten partikeln
EP1444988A4 (en) 2001-11-13 2007-04-25 Takeda Pharmaceutical CANCER AGENT
NZ533434A (en) * 2001-11-14 2006-11-30 Alza Corp Thixotropic gel composition for injectable deposition
WO2003041757A2 (en) 2001-11-14 2003-05-22 Alza Corporation Catheter injectable depot compositions and uses thereof
RU2191573C1 (ru) * 2001-11-14 2002-10-27 Нестерук Владимир Викторович Способ получения антибактериального средства на основе доксициклина
IL163666A0 (en) 2002-02-22 2005-12-18 New River Pharmaceuticals Inc Active agent delivery systems and methods for protecting and administering active agents
US7617005B2 (en) 2002-04-08 2009-11-10 Ardian, Inc. Methods and apparatus for thermally-induced renal neuromodulation
US8150519B2 (en) 2002-04-08 2012-04-03 Ardian, Inc. Methods and apparatus for bilateral renal neuromodulation
US8145317B2 (en) 2002-04-08 2012-03-27 Ardian, Inc. Methods for renal neuromodulation
US8347891B2 (en) 2002-04-08 2013-01-08 Medtronic Ardian Luxembourg S.A.R.L. Methods and apparatus for performing a non-continuous circumferential treatment of a body lumen
US7653438B2 (en) 2002-04-08 2010-01-26 Ardian, Inc. Methods and apparatus for renal neuromodulation
US7162303B2 (en) 2002-04-08 2007-01-09 Ardian, Inc. Renal nerve stimulation method and apparatus for treatment of patients
US8131371B2 (en) 2002-04-08 2012-03-06 Ardian, Inc. Methods and apparatus for monopolar renal neuromodulation
US7853333B2 (en) 2002-04-08 2010-12-14 Ardian, Inc. Methods and apparatus for multi-vessel renal neuromodulation
US8175711B2 (en) 2002-04-08 2012-05-08 Ardian, Inc. Methods for treating a condition or disease associated with cardio-renal function
US9308044B2 (en) 2002-04-08 2016-04-12 Medtronic Ardian Luxembourg S.A.R.L. Methods for therapeutic renal neuromodulation
US20070135875A1 (en) 2002-04-08 2007-06-14 Ardian, Inc. Methods and apparatus for thermally-induced renal neuromodulation
US8145316B2 (en) 2002-04-08 2012-03-27 Ardian, Inc. Methods and apparatus for renal neuromodulation
US8774913B2 (en) 2002-04-08 2014-07-08 Medtronic Ardian Luxembourg S.A.R.L. Methods and apparatus for intravasculary-induced neuromodulation
US8774922B2 (en) 2002-04-08 2014-07-08 Medtronic Ardian Luxembourg S.A.R.L. Catheter apparatuses having expandable balloons for renal neuromodulation and associated systems and methods
US9636174B2 (en) 2002-04-08 2017-05-02 Medtronic Ardian Luxembourg S.A.R.L. Methods for therapeutic renal neuromodulation
US7756583B2 (en) 2002-04-08 2010-07-13 Ardian, Inc. Methods and apparatus for intravascularly-induced neuromodulation
US20140018880A1 (en) 2002-04-08 2014-01-16 Medtronic Ardian Luxembourg S.A.R.L. Methods for monopolar renal neuromodulation
US20070129761A1 (en) 2002-04-08 2007-06-07 Ardian, Inc. Methods for treating heart arrhythmia
US6978174B2 (en) 2002-04-08 2005-12-20 Ardian, Inc. Methods and devices for renal nerve blocking
US9308043B2 (en) 2002-04-08 2016-04-12 Medtronic Ardian Luxembourg S.A.R.L. Methods for monopolar renal neuromodulation
US20080213331A1 (en) 2002-04-08 2008-09-04 Ardian, Inc. Methods and devices for renal nerve blocking
US7620451B2 (en) 2005-12-29 2009-11-17 Ardian, Inc. Methods and apparatus for pulsed electric field neuromodulation via an intra-to-extravascular approach
MXPA04009968A (es) 2002-04-09 2004-12-13 Flamel Tech Sa Formulacion farmaceutica oral bajo forma de suspension acuosa de microcapsulas que permiten la liberacion modificada de principio (s) activo (s).
US8623393B2 (en) * 2002-04-29 2014-01-07 Gel-Del Technologies, Inc. Biomatrix structural containment and fixation systems and methods of use thereof
US8871241B2 (en) 2002-05-07 2014-10-28 Psivida Us, Inc. Injectable sustained release delivery devices
FR2840614B1 (fr) * 2002-06-07 2004-08-27 Flamel Tech Sa Polyaminoacides fonctionnalises par de l'alpha-tocopherol et leurs applications notamment therapeutiques
US20030228366A1 (en) * 2002-06-11 2003-12-11 Chung Shih Reconstitutable compositions of biodegradable block copolymers
US7649023B2 (en) 2002-06-11 2010-01-19 Novartis Ag Biodegradable block copolymeric compositions for drug delivery
US7166133B2 (en) 2002-06-13 2007-01-23 Kensey Nash Corporation Devices and methods for treating defects in the tissue of a living being
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
PT1532985T (pt) 2002-06-25 2017-01-20 Takeda Pharmaceuticals Co Processo de produção de uma composição de libertação sustentada
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
US7160551B2 (en) * 2002-07-09 2007-01-09 The Board Of Trustees Of The University Of Illinois Injectable system for controlled drug delivery
FR2843117B1 (fr) 2002-07-30 2004-10-15 Flamel Tech Sa Polyaminoacides fonctionnalises par au moins un groupement hydrophobe et leurs applications notamment therapeutiques
WO2004011054A2 (en) 2002-07-31 2004-02-05 Alza Corporation Injectable multimodal polymer depot compositions and uses thereof
KR20050038008A (ko) 2002-07-31 2005-04-25 알자 코포레이션 주사용 저장형 조성물 및 이의 용도
CA2494281A1 (en) * 2002-08-02 2004-02-12 Penwest Pharmaceuticals Company Sustained release formulations of metformin
EP2277551B1 (en) 2002-09-06 2013-05-08 Cerulean Pharma Inc. Cyclodextrin-based polymers for delivering the therapeutic agents covalently bound thereto
WO2004053056A2 (en) * 2002-09-24 2004-06-24 University Of Kentucky Research Foundation Nanoparticle-based vaccine delivery system containing adjuvant
US20040086566A1 (en) * 2002-11-04 2004-05-06 Alpharma, Inc. Waxy matrix dosage forms
KR100709015B1 (ko) * 2002-11-13 2007-04-18 (주)아모레퍼시픽 지속적 약물방출이 가능한 고분자 미립구 및 그 제조방법
CA2505951A1 (en) * 2002-11-14 2004-05-27 Shear/Kershman Laboratories, Inc Oral testosterone delivery system with improved sustained release
JP4970731B2 (ja) * 2002-12-04 2012-07-11 フラメル・テクノロジー 少なくとも１つの（オリゴ）アミノ酸基によって官能性をもたせたポリアミノ酸およびこれらの適用、特に医療適用
WO2004057959A2 (en) 2002-12-20 2004-07-15 Generipharm, Inc. Intracutaneous injection
CA2510320C (en) * 2002-12-20 2012-10-09 St. James Associates Llc/Faber Research Series Coated particles for sustained-release pharmaceutical administration
CA2553699A1 (en) * 2003-02-11 2005-08-26 Venture Management Alliance, Llc Material incapsulation system
WO2004081196A2 (en) * 2003-03-11 2004-09-23 Qlt Usa Inc. Formulations for cell- schedule dependent anticancer agents
US9445901B2 (en) * 2003-03-12 2016-09-20 Deger C. Tunc Prosthesis with sustained release analgesic
KR20050115315A (ko) * 2003-03-26 2005-12-07 가부시키가이샤 엘티티 바이오파마 약물 전달 및 서방성 약물 방출을 표적으로 하는 정맥 내 나노입자
JP2006521366A (ja) * 2003-03-28 2006-09-21 シグモイド・バイオテクノロジーズ・リミテッド シームレスマイクロカプセルを含む固形経口剤形
JP2004331750A (ja) 2003-05-02 2004-11-25 Canon Inc ポリヒドロキシアルカノエートを含有する磁性構造体及びその製造方法ならびにその用途
FR2855521B1 (fr) 2003-05-28 2005-08-05 Flamel Tech Sa Polyaminoacides fonctionnalises par au moins un groupement h ydrophobe et leurs applications notamment therapeutiques.
US8834864B2 (en) 2003-06-05 2014-09-16 Baxter International Inc. Methods for repairing and regenerating human dura mater
US8465537B2 (en) * 2003-06-17 2013-06-18 Gel-Del Technologies, Inc. Encapsulated or coated stent systems
US20050142205A1 (en) * 2003-07-18 2005-06-30 Julia Rashba-Step Methods for encapsulating small spherical particles prepared by controlled phase separation
JP2008518881A (ja) 2003-07-18 2008-06-05 オークウッド ラボラトリーズ，エル．エル．シー． 高分子組成物中の高分子の分子量低下、不純物形成およびゲル化の防止
US20070092452A1 (en) * 2003-07-18 2007-04-26 Julia Rashba-Step Methods for fabrication, uses, compositions of inhalable spherical particles
WO2005035088A2 (en) * 2003-07-18 2005-04-21 Baxter International, Inc. Method for preparing small spherical by controlled phase separation
JP2007508240A (ja) * 2003-07-22 2007-04-05 バクスター・インターナショナル・インコーポレイテッド 低分子量有機分子の小球状粒子ならびにその調製方法および使用方法
US20090214644A1 (en) * 2003-07-31 2009-08-27 Xanodyne Pharmaceuticals, Inc. Tranexamic acid formulations with reduced adverse effects
US20050025825A1 (en) 2003-07-31 2005-02-03 Xanodyne Pharmacal, Inc. Tranexamic acid formulations with reduced adverse effects
US7927626B2 (en) * 2003-08-07 2011-04-19 Ethicon, Inc. Process of making flowable hemostatic compositions and devices containing such compositions
KR101087464B1 (ko) 2003-08-08 2011-11-25 밸리언트 인터내셔널(바베이도스) 에스알엘 부프로피온 히드로클로라이드의 개질 방출형 정제
US8153591B2 (en) * 2003-08-26 2012-04-10 Gel-Del Technologies, Inc. Protein biomaterials and biocoacervates and methods of making and using thereof
FR2860516B1 (fr) * 2003-10-03 2006-01-13 Flamel Tech Sa Homopolyaminoacides telecheliques fonctionnalises par des groupements hydrophobes et leurs applications notamment therapeutiques
US20050101605A1 (en) * 2003-11-07 2005-05-12 Ahmed Salah U. Oral liquid formulations of methotrexate
FR2862536B1 (fr) * 2003-11-21 2007-11-23 Flamel Tech Sa Formulations pharmaceutiques pour la liberation prolongee de principe(s) actif(s), ainsi que leurs applications notamment therapeutiques
WO2005055945A2 (en) * 2003-12-08 2005-06-23 Gel-Del Technologies, Inc. Mucoadhesive drug delivery devices and methods of making and using thereof
US20060074025A1 (en) * 2003-12-26 2006-04-06 Nastech Pharmaceutical Company Inc. Therapeutic formulations for transmucosal administration that increase glucagon-like peptide-1 bioavailability
US20050143303A1 (en) * 2003-12-26 2005-06-30 Nastech Pharmaceutical Company Inc. Intranasal administration of glucose-regulating peptides
US20060210614A1 (en) * 2003-12-26 2006-09-21 Nastech Pharmaceutical Company Inc. Method of treatment of a metabolic disease using intranasal administration of exendin peptide
US20080318837A1 (en) * 2003-12-26 2008-12-25 Nastech Pharmaceutical Company Inc. Pharmaceutical Formation For Increased Epithelial Permeability of Glucose-Regulating Peptide
TW200529890A (en) * 2004-02-10 2005-09-16 Takeda Pharmaceutical Sustained-release preparations
LT2351555T (lt) 2004-02-23 2016-12-27 Euro-Celtique S.A. Piktnaudžiavimui atspari priemonė, skirta transderminiam opoido įvedimui
US20050208134A1 (en) * 2004-02-25 2005-09-22 Shlomo Magdassi Biocompatible polymeric beads and use thereof
US7947739B2 (en) 2004-03-04 2011-05-24 Ferring B.V. Tranexamic acid formulations
US20090215898A1 (en) * 2004-03-04 2009-08-27 Xanodyne Pharmaceuticals, Inc. Tranexamic acid formulations
US8022106B2 (en) * 2004-03-04 2011-09-20 Ferring B.V. Tranexamic acid formulations
US20050244495A1 (en) 2004-03-04 2005-11-03 Xanodyne Pharmaceuticals, Inc. Tranexamic acid formulations
US20050245614A1 (en) * 2004-03-04 2005-11-03 Xanodyne Pharmaceuticals, Inc. Tranexamic acid formulations
WO2005094789A1 (ja) * 2004-03-31 2005-10-13 Aspion Co., Ltd. Ｓ／ｏ型製剤およびその製造方法
GB0408308D0 (en) 2004-04-14 2004-05-19 Vectura Ltd Pharmaceutical compositions
WO2005107714A2 (en) * 2004-05-05 2005-11-17 Alkermes Controlled Therapeutics, Inc. Method of forming microparticles that include a bisphosphonate and a polymer
WO2005112885A2 (en) * 2004-05-12 2005-12-01 Baxter International Inc. Oligonucleotide-containing microspheres, their use for the manufacture of a medicament for treating diabetes type 1
EP1753404A1 (en) * 2004-05-12 2007-02-21 Baxter International Inc. Microspheres comprising protein and showing injectability at high concentrations of said agent
CA2566079A1 (en) * 2004-05-12 2005-12-01 Terrence L. Scott Nucleic acid microspheres, production and delivery thereof
US8728525B2 (en) * 2004-05-12 2014-05-20 Baxter International Inc. Protein microspheres retaining pharmacokinetic and pharmacodynamic properties
EP1768668A2 (en) 2004-06-16 2007-04-04 Tap Pharmaceutical Products, Inc. Multiple ppi dosage form
US7740861B2 (en) * 2004-06-16 2010-06-22 University Of Massachusetts Drug delivery product and methods
TW200613012A (en) * 2004-07-02 2006-05-01 Takeda Pharmaceuticals Co Sustained-release composition, process for producing the same and use of the same
EP3417895A1 (en) 2004-07-28 2018-12-26 Medtronic Ardian Luxembourg S.à.r.l. Methods and devices for renal nerve blocking
FR2873703B1 (fr) * 2004-07-30 2006-12-08 Flamel Technologies Sa Polyaminoacides branches, fonctionnalises par des groupements hydrophobes et leurs applications notamment therapeutiques
FR2873704B1 (fr) * 2004-07-30 2006-12-08 Flamel Technologies Sa Polyaminoacides fonctionnalises par des greffons hydrophobes portant une charge anionique et leurs applications notamment therapeutiques
BRPI0515191A (pt) * 2004-08-13 2008-07-08 Angiotech Internac Ag composição farmacêutica, método para aumentar osso ou substituir perda óssea, método para reduzir a dor associada com cicatriz pós-cirúrgica, método para prevenir aderência cirúrgicas, método para aumento ou reparo de pele ou tecido, método para manter volume em fluido ocular durante cirurgia ocular, método para reduzir a dor associada com osteoartrite, método para tratar doença de refluxo gastroesofágico, método para tratar ou prevenir incontinência urinária, método para tratar ou prevenir incontinência fecal, implante método e dispositivo médico
WO2006025583A1 (ja) * 2004-08-31 2006-03-09 Aspion Co., Ltd. Ｓ／ｏ型外用剤
US20070254314A1 (en) * 2004-09-16 2007-11-01 Geier Mark R Methods of treating autism and autism spectrum disorders
ES2375995T3 (es) * 2004-09-17 2012-03-08 University Of Massachusetts Composiciones y sus usos para deficiencias de enzima lisosomal.
CA2581816A1 (en) * 2004-09-27 2006-04-06 Sigmoid Biotechnologies Limited Microcapsules comprising a methylxanthine and a corticosteroid
US8313763B2 (en) * 2004-10-04 2012-11-20 Tolmar Therapeutics, Inc. Sustained delivery formulations of rapamycin compounds
WO2006041942A2 (en) * 2004-10-04 2006-04-20 Qlt Usa, Inc. Ocular delivery of polymeric delivery formulations
ES2255426B1 (es) * 2004-10-19 2007-08-16 Gp Pharm, S.A. Formulacion farmaceutica que comprende microcapsulas de estatinas suspendidas en ester alquilicos de acidos grasos poliinsaturados (pufa).
US20060115485A1 (en) * 2004-10-29 2006-06-01 Medimmune, Inc. Methods of preventing and treating RSV infections and related conditions
US7937143B2 (en) 2004-11-02 2011-05-03 Ardian, Inc. Methods and apparatus for inducing controlled renal neuromodulation
EP1824460B1 (en) 2004-11-10 2014-12-24 Tolmar Therapeutics, Inc. A stabilized polymeric delivery system
ATE401537T1 (de) * 2005-01-06 2008-08-15 Halton Oy Belüftungsregister und belüftungssysteme
FR2881140B1 (fr) * 2005-01-27 2007-04-06 Flamel Technologies Sa Copolyhydroxyalkylglutamines fonctionnalises par des groupements hydrophobes et leurs applications notamment therapeutiques
MX2007013356A (es) * 2005-04-27 2008-03-26 Baxter Int Microparticulas modificadas en la superficie y metodos de formacion y uso de las mismas.
US8017152B2 (en) 2005-05-27 2011-09-13 Stratosphere Pharma Ab Cores and microcapsules suitable for parenteral administration as well as process for their manufacture
EP1726299A3 (en) * 2005-05-27 2007-04-18 StratoSphere Pharma AB Cores and microcapsules suitable for parenteral administration as well as process for their manufacture
US8039462B2 (en) 2005-09-19 2011-10-18 Neuronascent, Inc. Methods and compositons for stimulating neurogenesis and inhibiting neuronal degeneration
EP1948245B1 (en) * 2005-10-24 2011-10-05 University of Massachusetts Compositions and their uses for gene therapy of bone conditions
FR2892725B1 (fr) * 2005-10-31 2011-03-04 Flamel Tech Sa Acides polyglutamiques fonctionnalises par des derives de l'histidine et des groupements hydrophobes et leurs applications notamment therapeutiques
US20070106271A1 (en) * 2005-11-09 2007-05-10 Searete Llc, A Limited Liability Corporation Remote control of substance delivery system
US20080286375A1 (en) * 2005-11-15 2008-11-20 Amorepacific Corporation Method for Preparing Sustained-Release Microparticles Comprising Sucrose Acetate Isobutyrate
US8546451B2 (en) 2005-11-28 2013-10-01 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
US8637706B2 (en) 2005-11-28 2014-01-28 Gtx, Inc. Nuclear receptor binding agents
US9409856B2 (en) 2005-11-28 2016-08-09 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
WO2007067964A2 (en) * 2005-12-08 2007-06-14 Nastech Pharmaceutical Company Inc. Mucosal delivery of stabilized formulations of exendin
WO2007074604A1 (ja) * 2005-12-26 2007-07-05 Ltt Bio-Pharma Co., Ltd. 水溶性非ペプチド性低分子薬物含有ナノ粒子
CU23388B6 (es) 2006-01-31 2009-07-16 Ct Ingenieria Genetica Biotech Composición farmacéutica de microesferas para prevenir la amputación del pie diabético
KR100722607B1 (ko) 2006-05-11 2007-05-28 주식회사 펩트론 분산성 및 주사 투여능이 향상된 서방성 미립구의 제조방법
US9023400B2 (en) * 2006-05-24 2015-05-05 Flamel Technologies Prolonged-release multimicroparticulate oral pharmaceutical form
JP4720620B2 (ja) * 2006-05-30 2011-07-13 コニカミノルタビジネステクノロジーズ株式会社 カール補正装置及びこれを備えた画像形成装置
BRPI0712088B8 (pt) 2006-05-31 2021-06-22 Baxter Healthcare Sa uso de uma biomatriz de lâmina de colágeno de múltiplas camadas microscópicas não porosa e hermética a fluido
US20070281031A1 (en) * 2006-06-01 2007-12-06 Guohan Yang Microparticles and methods for production thereof
TWI436793B (zh) 2006-08-02 2014-05-11 巴克斯特國際公司 快速作用之乾密封膠及其使用和製造方法
EP2647712A3 (en) * 2006-08-04 2013-11-20 Baxter International Inc Microsphere-based composition for preventing and/or reversing new-onset autoimmune diabetes
WO2008060786A2 (en) * 2006-10-06 2008-05-22 Baxter International Inc. Microencapsules containing surface-modified microparticles and methods of forming and using the same
JP5196760B2 (ja) * 2006-10-27 2013-05-15 一般財団法人 九州医療資源財団 Ｗ／ｏ／ｗ型エマルジョン組成物
US7695929B2 (en) 2006-11-01 2010-04-13 Ventana Medical Systems, Inc. Haptens, hapten conjugates, compositions thereof and method for their preparation and use
US9289196B2 (en) 2006-12-12 2016-03-22 Cook Medical Technologies Llc Hemostatic substance with a coating
JP4564098B2 (ja) 2006-12-18 2010-10-20 武田薬品工業株式会社 徐放性組成物およびその製造法
US20080176958A1 (en) 2007-01-24 2008-07-24 Insert Therapeutics, Inc. Cyclodextrin-based polymers for therapeutics delivery
EP2061440A2 (en) 2007-04-04 2009-05-27 Sigmoid Pharma Limited A pharmaceutical composition of tacrolimus
ES2963291T3 (es) 2007-04-26 2024-03-26 Sublimity Therapeutics Ltd Fabricación de múltiples minicápsulas
CA2685591A1 (en) * 2007-05-01 2008-11-06 Sigmoid Pharma Limited Pharmaceutical nimodipine compositions
FR2915748B1 (fr) 2007-05-03 2012-10-19 Flamel Tech Sa Acides polyglutamiques fonctionnalises par des groupes cationiques et des groupements hydrophobes et leurs applications, notamment therapeutiques
KR101513318B1 (ko) * 2007-05-14 2015-04-17 가부시키가이샤 엘티티 바이오파마 서방성의 음하전기를 갖는 저분자 약물 함유 나노 입자
EP1997830A1 (en) * 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
US20080318993A1 (en) * 2007-06-21 2008-12-25 Endo Pharmaceuticals, Inc. Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instruction on Dosing for Hepatic Impairment
US20080318994A1 (en) 2007-06-21 2008-12-25 Endo Pharmaceuticals, Inc. Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instruction on Dosing for Renal Impairment
ES2564826T3 (es) 2007-06-21 2016-03-29 Neuronascent, Inc. Métodos y composiciones para estimular neurogénesis e inhibir degeneración neuronal utilizando isotiazolopirimidinonas
US10011763B2 (en) 2007-07-25 2018-07-03 Schlumberger Technology Corporation Methods to deliver fluids on a well site with variable solids concentration from solid slurries
US9040468B2 (en) 2007-07-25 2015-05-26 Schlumberger Technology Corporation Hydrolyzable particle compositions, treatment fluids and methods
WO2009028650A1 (ja) * 2007-08-29 2009-03-05 Yutoku Pharmaceutical Industries Co., Ltd. 乳化型外用剤およびその製造方法
CN102014638A (zh) * 2007-10-12 2011-04-13 武田制药北美公司 与食物摄入无关的治疗胃肠病症的方法
EP2222283A2 (en) * 2007-10-29 2010-09-01 University of Massachusetts Yeast cell wall protein (ycwp) encapsulated multilayered nanoparticles for nucleic acid delivery (sirna)
AR069109A1 (es) 2007-10-30 2009-12-30 Baxter Int Uso de una biomatriz de colageno biofuncional regenerativa para tratar defectos viscerales o parietales
WO2009075652A1 (en) * 2007-12-11 2009-06-18 Nanyang Technological University Hollow multi-layered microspheres for delivery of hydrophilic active compounds
WO2009086483A2 (en) * 2007-12-26 2009-07-09 Gel-Del Technologies, Inc. Biocompatible protein particles, particle devices and methods thereof
CA2710515A1 (en) * 2007-12-28 2009-07-09 Khashayar Kevin Neshat Controlled release local anesthetic for post dental surgery and method of use
WO2009100422A2 (en) * 2008-02-08 2009-08-13 Zimmer, Inc. Drug delivery system comprising microparticles and gelation system
ES2397016B1 (es) * 2008-02-18 2014-01-17 Csir Transportadores de nanopartículas para administración de fármacos y procedimiento para producir las mismas.
WO2009109194A2 (en) 2008-02-29 2009-09-11 Ferrosan A/S Device for promotion of hemostasis and/or wound healing
KR100963435B1 (ko) * 2008-06-19 2010-06-17 한국과학기술연구원 서방형 약물전달 및 조직재생용 덮인 다공성 생분해성고분자 미립구의 제조 방법
CA2730760A1 (en) * 2008-07-16 2010-01-21 Surmodics Pharmaceuticals, Inc. Process for preparing microparticles containing bioactive peptides
WO2010008582A2 (en) 2008-07-18 2010-01-21 Rxi Pharmaceuticals Corporation Phagocytic cell drug delivery system
US8034382B2 (en) * 2008-07-31 2011-10-11 The Board Of Trustees Of The University Of Arkansas Preparation method for biodegradable micro-particles containing drugs
US8367427B2 (en) * 2008-08-20 2013-02-05 Baxter International Inc. Methods of processing compositions containing microparticles
US8323615B2 (en) * 2008-08-20 2012-12-04 Baxter International Inc. Methods of processing multi-phasic dispersions
US8323685B2 (en) * 2008-08-20 2012-12-04 Baxter International Inc. Methods of processing compositions containing microparticles
US20100047292A1 (en) * 2008-08-20 2010-02-25 Baxter International Inc. Methods of processing microparticles and compositions produced thereby
US20100062057A1 (en) * 2008-09-10 2010-03-11 Pronova BioPharma Norge AS. Formulation
EP2340309A2 (en) 2008-09-22 2011-07-06 Rxi Pharmaceuticals Corporation Neutral nanotransporters
US8741259B2 (en) 2008-10-20 2014-06-03 Marvin C. Gershengorn Low molecular weight thyroid stimulating hormone receptor (TSHR) agonists
US8653086B2 (en) 2008-10-21 2014-02-18 Oregon Health & Science University Naphthamides as anticancer agents
WO2010057177A2 (en) 2008-11-17 2010-05-20 Gel-Del Technologies, Inc. Protein biomaterial and biocoacervate vessel graft systems and methods of making and using thereof
US8652129B2 (en) 2008-12-31 2014-02-18 Medtronic Ardian Luxembourg S.A.R.L. Apparatus, systems, and methods for achieving intravascular, thermally-induced renal neuromodulation
US9493774B2 (en) 2009-01-05 2016-11-15 Rxi Pharmaceuticals Corporation Inhibition of PCSK9 through RNAi
WO2010085607A1 (en) * 2009-01-23 2010-07-29 Surmodics Pharmaceuticals, Inc. Continuous double emulsion process for making microparticles
WO2010090762A1 (en) 2009-02-04 2010-08-12 Rxi Pharmaceuticals Corporation Rna duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
US9624161B2 (en) 2009-02-23 2017-04-18 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
US9427418B2 (en) 2009-02-23 2016-08-30 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
US9532963B2 (en) 2009-03-09 2017-01-03 Pronova Biopharma Norge As Compositions comprising a fatty acid oil mixture and a free fatty acid, and methods and uses thereof
US9814657B2 (en) 2009-04-27 2017-11-14 Premier Dental Products Company Buffered microencapsulated compositions and methods
CA2759275C (en) * 2009-04-27 2017-09-19 Premier Dental Products Company Microencapsulated compositions and methods for tissue mineralization
US20100280117A1 (en) * 2009-04-30 2010-11-04 Xanodyne Pharmaceuticals, Inc. Menorrhagia Instrument and Method for the Treatment of Menstrual Bleeding Disorders
ES2530049T3 (es) 2009-05-18 2015-02-26 Sigmoid Pharma Limited Composición que comprende gotas de aceite
US9039783B2 (en) 2009-05-18 2015-05-26 Baxter International, Inc. Method for the improvement of mesh implant biocompatibility
DK2442835T3 (en) 2009-06-16 2015-03-16 Baxter Int Styptic sponge
BR112012002963A2 (pt) 2009-08-12 2017-10-24 Sigmoid Pharma Ltd composições imunomoduladoras compreendendo uma matriz de polímero e uma fase oleosa
GB0915480D0 (en) * 2009-09-04 2009-10-07 Arecor Ltd Stable formulation of factor viii
CA2939165A1 (en) 2009-09-15 2011-03-24 Cerulean Pharma Inc. A cdp-camptothecin conjugate, particle or composition and uses thereof
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
ES2364011B1 (es) 2009-11-20 2013-01-24 Gp Pharm, S.A. Cápsulas de principios activos farmacéuticos y ésteres de ácidos grasos poliinsaturados para el tratamiento de enfermedades cardiovasculares.
ES2363964B1 (es) 2009-11-20 2012-08-22 Gp Pharm, S.A. Cápsulas de principios activos farmacéuticos y ésteres de ácidos grasos poliinsaturados.
ES2363965B1 (es) 2009-11-20 2013-01-24 Gp Pharm S.A. Cápsulas de principios activos betabloqueantes y ésteres de ácidos grasos poliinsaturados.
EP2503888A4 (en) * 2009-11-23 2015-07-29 Cerulean Pharma Inc POLYMERS ON CYCLODEXTRINBASIS FOR THERAPEUTIC ADMINISTRATION
BR112012014773A2 (pt) 2009-12-16 2015-11-03 Baxter Healthcare Sa esponja de compósito hemostática, método para fabricar uma esponja de compósito hemostática, e, uso da referida esponja
SG181446A1 (en) 2009-12-23 2012-07-30 Defiante Farmaceutica Sa Combination composition useful for treating cardiovascular diseases
WO2011079232A1 (en) * 2009-12-23 2011-06-30 Psivida Us, Inc. Sustained release delivery devices
EP2353588B1 (en) * 2010-01-21 2015-04-15 Agricultural Technology Research Institute A sustained release preparation of factor IX
US9365612B2 (en) 2010-01-29 2016-06-14 United States Of America As Represented By The Secretary, Department Of Health And Human Services Caspase inhibitors
US9205577B2 (en) * 2010-02-05 2015-12-08 Allergan, Inc. Porogen compositions, methods of making and uses
US9138309B2 (en) 2010-02-05 2015-09-22 Allergan, Inc. Porous materials, methods of making and uses
HUE042593T2 (hu) * 2010-03-09 2019-07-29 Alkermes Pharma Ireland Ltd Alkoholnak ellenálló enterális gyógyszerkészítmények
HUE033144T2 (en) 2010-03-12 2017-11-28 Monsanto Technology Llc Agrochemical gel preparations
CN101816910B (zh) * 2010-03-25 2011-12-07 陕西师范大学 固载十六烷基三甲基磷钨酸季铵盐杂化微凝胶的制备方法
SA111320355B1 (ar) 2010-04-07 2015-01-08 Baxter Heathcare S A إسفنجة لايقاف النزف
EP2563777A4 (en) 2010-04-08 2013-09-04 Us Health INVERSE AGONISTS AND NEUTRAL AGONISTS FOR THE TSH RECEPTOR
US11202853B2 (en) * 2010-05-11 2021-12-21 Allergan, Inc. Porogen compositions, methods of making and uses
CN103037903A (zh) 2010-05-18 2013-04-10 天蓝制药公司 用于治疗自身免疫性疾病或其它疾病的组合物和方法
MX352875B (es) 2010-06-01 2017-12-13 Baxter Healthcare Sa Proceso para elaborar composiciones hemostaticas secas y estables.
AU2011260258B2 (en) 2010-06-01 2015-07-09 Baxter Healthcare S.A. Process for making dry and stable hemostatic compositions
CA2801118C (en) 2010-06-01 2016-01-05 Baxter International Inc. Process for making dry and stable hemostatic compositions
ES2385240B1 (es) 2010-07-26 2013-09-23 Gp-Pharm, S.A. Cápsulas de principios activos farmacéuticos y ácidos grasos poliinsaturados para el tratamiento de enfermedades de la próstata.
WO2012024229A1 (en) 2010-08-14 2012-02-23 University Of Massachusetts Yeast cell wall particle for receptor-targeted nanoparticle delivery
GB201016433D0 (en) 2010-09-30 2010-11-17 Q Chip Ltd Apparatus and method for making solid beads
GB201016436D0 (en) 2010-09-30 2010-11-17 Q Chip Ltd Method of making solid beads
US9132291B2 (en) 2010-10-05 2015-09-15 Dfb Technology, Ltd. Water-in-oil emulsion compositions containing gellan gum for topical delivery of active ingredients to the skin or mucosa
CN107007348B (zh) 2010-10-25 2019-05-31 美敦力Af卢森堡有限责任公司 用于神经调节治疗的估算及反馈的装置、系统及方法
GB201020032D0 (en) 2010-11-25 2011-01-12 Sigmoid Pharma Ltd Composition
US9648874B2 (en) 2010-12-07 2017-05-16 Kimberly-Clark Worldwide, Inc. Natural, multiple use and re-use, user saturated wipes
US9832993B2 (en) 2010-12-07 2017-12-05 Kimberly-Clark Worldwide, Inc. Melt processed antimicrobial composition
US9149045B2 (en) 2010-12-07 2015-10-06 Kimberly-Clark Worldwide, Inc. Wipe coated with a botanical emulsion having antimicrobial properties
US8524264B2 (en) 2010-12-07 2013-09-03 Kimberly-Clark Worldwide, Inc. Protein stabilized antimicrobial composition formed by melt processing
US10821085B2 (en) 2010-12-07 2020-11-03 Kimberly-Clark Worldwide, Inc. Wipe coated with a botanical composition having antimicrobial properties
US8445032B2 (en) 2010-12-07 2013-05-21 Kimberly-Clark Worldwide, Inc. Melt-blended protein composition
WO2012125486A1 (en) 2011-03-11 2012-09-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Combination chemotherapy for treating cancer
EP2685985B1 (en) 2011-03-17 2016-08-31 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Methods for treating leukemia and disorders mediated by cbf and runx1 proteins
WO2013039792A1 (en) 2011-09-12 2013-03-21 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Immunogens based on an hiv-1 gp120 v1v2 epitope
US20140234360A1 (en) 2011-09-30 2014-08-21 The United States of America, as represented by the Secretary, Dept.of Health and Human Services Influenza vaccine
CA2851321C (en) 2011-10-11 2020-07-07 Baxter International Inc. Hemostatic compositions
HK1201212A1 (en) 2011-10-11 2015-08-28 Baxter International Inc Hemostatic compositions
US9877929B2 (en) 2011-10-13 2018-01-30 Premier Dental Products Company Topical vitamin D and ubiquinol oral supplement compositions
ES2553702T3 (es) 2011-10-27 2015-12-11 Baxter International Inc Composiciones hemostáticas
WO2013072767A1 (en) 2011-11-18 2013-05-23 Pronova Biopharma Norge As Compositions and preconcentrates comprising at least one salicylate and omega-3 fatty acid oil mixture
US8574628B2 (en) 2011-12-19 2013-11-05 Kimberly-Clark Worldwide, Inc. Natural, multiple release and re-use compositions
US9249103B2 (en) 2012-01-13 2016-02-02 Oregon Health & Science University Compounds, compositions and associated methods comprising 3-aryl quinolines
JP6241624B2 (ja) 2012-03-06 2017-12-06 フェロサン メディカル デバイシーズ エイ／エス 止血ペーストを収容する加圧容器
EP3348220B1 (en) 2012-03-08 2024-10-23 Medtronic Ardian Luxembourg S.à.r.l. Biomarker sampling in the context of neuromodulation devices and associated systems
AU2013230781B2 (en) 2012-03-08 2015-12-03 Medtronic Af Luxembourg S.A.R.L. Ovarian neuromodulation and associated systems and methods
US8979991B2 (en) 2012-03-21 2015-03-17 Loma Linda University Substances and method for replacing natural tooth material
EP2833740B1 (en) 2012-04-04 2016-09-14 Pronova BioPharma Norge AS Compositions comprising omega-3 fatty acids and vitamin d for acne vulgaris and/or eczema, and methods and uses thereof
US9585896B2 (en) 2012-04-04 2017-03-07 Pronova Biopharma Norge As Compositions comprising omega-3 fatty acids and vitamin D for psoriasis, and methods and uses thereof
WO2013184202A1 (en) 2012-06-08 2013-12-12 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Fbxo3 inhibitors
CN104349797B (zh) 2012-06-12 2017-10-27 弗罗桑医疗设备公司 干止血组合物
GB201212010D0 (en) 2012-07-05 2012-08-22 Sigmoid Pharma Ltd Formulations
US20140094432A1 (en) 2012-10-02 2014-04-03 Cerulean Pharma Inc. Methods and systems for polymer precipitation and generation of particles
US9724542B2 (en) 2012-10-12 2017-08-08 Premier Dental Products Company Remineralizing and desensitizing compositions, treatments and methods of manufacture
US9877930B2 (en) 2012-10-12 2018-01-30 Premier Dental Products Company Topical ubiquinol oral supplement compositions with amorphous calcium phosphate
US20140110296A1 (en) 2012-10-19 2014-04-24 Medtronic Ardian Luxembourg S.A.R.L. Packaging for Catheter Treatment Devices and Associated Devices, Systems, and Methods
CA2889697C (en) 2012-11-13 2023-03-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Cannabinoid receptor mediating compounds
US20140142522A1 (en) * 2012-11-16 2014-05-22 NU Technology, LLC Moist dressing with honeycomb pattern and drain channels
US9775895B2 (en) 2012-12-12 2017-10-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services HIV therapeutics and methods of making and using same
AU2014222389B2 (en) 2013-02-28 2018-11-29 Pronova Biopharma Norge As A composition comprising a lipid compound, a triglyceride, and a surfactant, and methods of using the same
PT2970398T (pt) 2013-03-13 2024-06-07 The Us Secretary Department Ofhealth And Human Servic Proteínas f de pré-fusão do vsr e sua utilização
KR101486132B1 (ko) 2013-03-20 2015-01-23 씨제이헬스케어 주식회사 졸-겔 변환 특성을 갖는 고분자를 이용한 미립구의 제조방법 및 이로부터 제조된 미립구
CA2907765C (en) 2013-03-21 2021-07-06 Eupraxia Pharmaceuticals USA LLC Injectable sustained release composition and method of using the same for treating inflammation in joints and pain associated therewith
KR101543507B1 (ko) 2013-05-15 2015-08-11 씨제이헬스케어 주식회사 연속 공정의 미립구의 제조 방법 및 이로부터 제조된 미립구
BR112015028760A2 (pt) 2013-05-16 2017-07-25 Us Health compostos para inibição de cepas de integrase do hiv-1 resistentes a drogas
EP3010419B1 (en) 2013-06-21 2020-05-20 Ferrosan Medical Devices A/S Vacuum expanded dry composition and syringe for retaining same
MX2016001607A (es) 2013-08-06 2016-06-06 Dong Kook Pharm Co Ltd Microesferas de entecavir y composicion farmaceutica para administracion parenteral que contiene las mismas.
CN103432093B (zh) * 2013-08-31 2015-03-25 西南大学 甲磺酸普立地诺骨架缓释片及其制备方法
EP3046561B1 (en) 2013-09-20 2023-02-22 University of Pittsburgh - Of the Commonwealth System of Higher Education Compounds for treating prostate cancer
ES2968371T3 (es) 2013-10-10 2024-05-09 Eastern Virginia Medical School Derivados de 4-((2-hidroxi-3-metoxibencil)amino) bencenosulfonamida como inhibidores de la 12-lipoxigenasa
GB201319791D0 (en) 2013-11-08 2013-12-25 Sigmoid Pharma Ltd Formulations
US20160303242A1 (en) 2013-12-09 2016-10-20 Durect Corporation Pharmaceutically Active Agent Complexes, Polymer Complexes, and Compositions and Methods Involving the Same
EP3079731B1 (en) 2013-12-11 2018-08-08 Ferrosan Medical Devices A/S Dry composition comprising an extrusion enhancer
US10398772B2 (en) 2014-01-08 2019-09-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Ras pathways as markers of protection against HIV and methods to improve vaccine efficacy
US9980766B1 (en) 2014-03-28 2018-05-29 Medtronic Ardian Luxembourg S.A.R.L. Methods and systems for renal neuromodulation
US10194980B1 (en) 2014-03-28 2019-02-05 Medtronic Ardian Luxembourg S.A.R.L. Methods for catheter-based renal neuromodulation
US10194979B1 (en) 2014-03-28 2019-02-05 Medtronic Ardian Luxembourg S.A.R.L. Methods for catheter-based renal neuromodulation
CN106170284A (zh) * 2014-03-31 2016-11-30 法尔玛赞公司 具有控释特征的装载肽的plga微球体的制备
CN106660968B (zh) 2014-05-09 2020-02-07 美国政府(由卫生和人类服务部的部长所代表) 吡唑衍生物及其作为大麻素受体介体的用途
ES2914099T3 (es) 2014-08-25 2022-06-07 Salk Inst For Biological Studi Inhibidores novedosos de ULK1 y métodos de uso de los mismos
WO2016037154A1 (en) 2014-09-04 2016-03-10 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Recombinant hiv-1 envelope proteins and their use
JP6726852B2 (ja) 2014-10-13 2020-07-22 フェッローサン メディカル ディバイス エー／エス 止血および創傷治癒に使用するための乾燥組成物
US20160106804A1 (en) * 2014-10-15 2016-04-21 Yuhua Li Pharmaceutical composition with improved stability
WO2016064716A1 (en) 2014-10-20 2016-04-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Combination therapy of tshr antagonist and igfr inhibitor
EA036036B1 (ru) 2014-11-07 2020-09-16 Сигмойд Фарма Лимитед Композиции, содержащие циклоспорин
RU2705905C2 (ru) 2014-12-24 2019-11-12 Ферросан Медикал Дивайсиз А/С Шприц для удерживания и смешивания первого и второго веществ
US10420834B2 (en) 2014-12-24 2019-09-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Recombinant metapneumovirus F proteins and their use
WO2016112036A1 (en) 2015-01-05 2016-07-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Myc g-quadruplex stabilizing small molecules and their use
JP2018510849A (ja) 2015-02-20 2018-04-19 オレゴン・ヘルス・アンド・サイエンス・ユニバーシティ ソベチロムの誘導体
US10093613B2 (en) 2015-04-21 2018-10-09 Gtx, Inc. Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US10017471B2 (en) 2015-04-21 2018-07-10 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
KR20170138536A (ko) 2015-04-21 2017-12-15 지티엑스, 인코포레이티드 선택적 안드로겐 수용체 분해제(sard) 리간드 및 이의 사용 방법
US10035763B2 (en) 2015-04-21 2018-07-31 Gtx, Inc. Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US10441570B2 (en) 2015-04-21 2019-10-15 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) Ligands and methods of use thereof
JP6786520B2 (ja) 2015-04-21 2020-11-18 ジーティーエックス・インコーポレイテッド 選択的アンドロゲン受容体分解剤（ｓａｒｄ）リガンド及びその使用方法
US10865184B2 (en) 2015-04-21 2020-12-15 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US9834507B2 (en) 2015-04-21 2017-12-05 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US10654809B2 (en) 2016-06-10 2020-05-19 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US10806720B2 (en) 2015-04-21 2020-10-20 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US20180104201A1 (en) 2015-04-28 2018-04-19 Pronova Biopharma Norge As Use of structurally enhanced fatty acids containing sulphur for preventing and or treating non alcoholic steatohepatitis
WO2016196646A1 (en) 2015-06-04 2016-12-08 The United States Of America, As Represented By The Secretary, Departmet Of Health & Human Services Cannabinoid receptor mediating compounds
CA2988405A1 (en) 2015-06-11 2016-12-15 University Of Pittsburgh - Of The Commonwealth System Of Higher Education P62-zz chemical inhibitor
AU2016290433B2 (en) 2015-07-03 2018-05-24 Ferrosan Medical Devices A/S Syringe for mixing two components and for retaining a vacuum in a storage condition
US10799580B2 (en) 2015-09-09 2020-10-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Expression vector delivery system and use thereof for inducing an immune response
TW201720427A (zh) 2015-10-27 2017-06-16 優普順藥物股份有限公司 局部麻醉劑之持續釋放調配物
EP3411022B1 (en) 2016-02-01 2021-09-15 Emory University Particles for targeted delivery and uses in managing bleeding or blood clotting
EP3423448B1 (en) 2016-03-04 2024-12-04 The U.S.A. as represented by the Secretary, Department of Health and Human Services Cannabinoid receptor mediating compounds
WO2017165822A1 (en) 2016-03-24 2017-09-28 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Small molecule inhibitor of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer
DK3457851T3 (da) 2016-05-18 2021-09-20 Univ Oregon Health & Science Derivater af sobetirom
US10806719B2 (en) 2016-06-10 2020-10-20 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
MX393924B (es) 2016-06-10 2025-03-24 Univ Tennessee Res Found Ligandos degradadores selectivos del receptor de andrógenos (sard) y métodos de uso de los mismos.
US11230523B2 (en) 2016-06-10 2022-01-25 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
EP3471828A1 (en) 2016-06-16 2019-04-24 Acies Bio d.o.o. Compositions and methods useful for treating diseases characterized by insufficient pantothenate kinase activity
WO2018109220A2 (en) 2016-12-16 2018-06-21 Institute For Research In Biomedicine Novel recombinant prefusion rsv f proteins and uses thereof
US11992482B2 (en) 2016-12-21 2024-05-28 Rilento Pharma, Llc Malleable controlled release local anesthetic with hemostatic composition
WO2018156459A1 (en) 2017-02-22 2018-08-30 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Compounds and methods for inhibiting emt pathways to treat cancer, organ fibrosis and metabolic disorders
US9962342B1 (en) * 2017-03-14 2018-05-08 Sunny Pharmtech Inc. Pharmaceutical composition containing guaifenesin and application thereof
JP7167059B2 (ja) 2017-04-19 2022-11-08 フィオ ファーマシューティカルズ コーポレーション 核酸化合物の局所送達
EP3687503A1 (en) 2017-09-26 2020-08-05 Nanomi B.V. Method for preparing micro-particles by double emulsion technique
IL274130B2 (en) 2017-11-01 2025-08-01 Scripps Research Inst Novel scaffolded hiv-1 vaccine immunogens
US11583497B2 (en) 2017-11-14 2023-02-21 The Schepens Eye Research Institute, Inc. Nano-emulsion of CBFß-RUNX1 inhibitor for ocular drug delivery
PT3720431T (pt) 2017-12-06 2024-12-05 Basf As Derivados de ácidos gordos para o tratamento da esteato-hepatite não alcoólica
WO2019118803A1 (en) 2017-12-14 2019-06-20 The United States Of America, As Represented By The Secretary,Department Of Health And Human Services Chemical entities for lytic activation of kshv and therapeutic targeting of viral enzymes/proteins
CN110123634A (zh) 2018-02-09 2019-08-16 株式会社理光 颗粒的制造方法，颗粒的制造装置，以及颗粒
SG11202008536QA (en) 2018-03-29 2020-10-29 Elex Biotech Inc Compounds for treatment of cardiac arrhythmias and heart failure
CN112368028A (zh) 2018-05-09 2021-02-12 弗罗桑医疗设备公司 用于制备止血组合物的方法
CA3100513A1 (en) 2018-05-16 2019-11-21 Gtx, Inc. Selective androgen receptor degrader (sard) ligands and methods of use thereof
FR3082842A1 (fr) 2018-06-21 2019-12-27 Veru Inc. Polymorphe de cis-clomiphene (zuclomiphene) et procedes d'utilisation de celui-ci
WO2020047277A1 (en) 2018-08-31 2020-03-05 Rilento Pharma, Llc Pharmaceutical formulation and system and method for delivery
WO2020051344A1 (en) 2018-09-05 2020-03-12 University Of Tennessee Research Foundation Selective androgen receptor degrader (sard) ligands and methods of use thereof
EP3856754A1 (en) 2018-09-25 2021-08-04 The United States of America, as represented by the Secretary, Department of Health and Human Services 2'-halogenated-4'-thio-2'-deoxy-5-azacytidine analogs and use thereof
WO2020123861A1 (en) 2018-12-12 2020-06-18 Autobahn Therapeutics, Inc. Novel thyromimetics
CN113784950A (zh) 2019-03-01 2021-12-10 速通医疗公司 新型拟甲状腺素药
EP3937917B1 (en) 2019-03-11 2023-11-15 Oregon State University Analogues and derivatives of cephalotaxine and methods for making and using the compounds
AU2020391467A1 (en) 2019-11-29 2022-06-23 Autobahn Therapeutics, Inc. Novel thyromimetics
CA3167217A1 (en) 2020-01-13 2021-07-22 Durect Corporation Sustained release drug delivery systems with reduced impurities and related methods
CN115515588A (zh) 2020-02-14 2022-12-23 萨克生物研究学院 大环ulk1/2抑制剂
EP4168384A4 (en) 2020-06-17 2024-07-10 Autobahn Therapeutics, Inc. THYROMIMETICS
EP4167986A4 (en) 2020-06-17 2024-11-20 Autobahn Therapeutics, Inc. THYROMIMETICS
WO2022029220A1 (en) 2020-08-05 2022-02-10 Ellipses Pharma Ltd Treatment of cancer using a cyclodextrin-containing polymer-topoisomerase inhibitor conjugate and a parp inhibitor
CN116940358A (zh) 2021-01-12 2023-10-24 度勒科特公司 持续释放药物递送系统和有关的方法
US11033495B1 (en) 2021-01-22 2021-06-15 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
US11357727B1 (en) 2021-01-22 2022-06-14 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
US12151024B2 (en) 2021-01-22 2024-11-26 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
US11278494B1 (en) 2021-01-22 2022-03-22 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
JP2024507528A (ja) 2021-02-24 2024-02-20 オークウッド ラボラトリーズ，エル．エル．シー． ルラシドンを含むミクロスフェア製剤ならびにその製造方法および使用方法
WO2022261296A1 (en) 2021-06-09 2022-12-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compounds that bind non-canonical g-quadruplex structures and methods of making and using the same
WO2023056368A1 (en) 2021-09-30 2023-04-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Cyclic peptides as non-hormonal male contraceptive agents and methods of use thereof
WO2023059867A1 (en) 2021-10-08 2023-04-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compounds for treating or preventing alzheimer's disease
GB2627096A (en) 2021-10-14 2024-08-14 Pacira Pharmaceuticals Inc Bupivacaine multivesicular liposome formulations and uses thereof
WO2023146771A1 (en) 2022-01-25 2023-08-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Gingerenone a prodrugs as senotherapeutics and methods of use
WO2023172751A1 (en) 2022-03-10 2023-09-14 University Of Massachusetts Devices and methods of treating wounds
EP4493547A1 (en) 2022-03-14 2025-01-22 The United States of America, as represented by the Secretary, Department of Health and Human Services Cannabinoid receptor modulating compounds
WO2024151855A1 (en) 2023-01-13 2024-07-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Bicyclic carbamoyl pyridone-based integrase strand transfer inhibitors
WO2025196270A1 (en) 2024-03-22 2025-09-25 Limmatech Biologics Ag Outer membrane vesicle vaccines for the prevention of n. gonorrhoeae and methods of making and using thereof
WO2025213007A1 (en) 2024-04-04 2025-10-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services S-hydroxychloroquine, optionally with tauroursodeoxycholic acid and/or 3,3'-diindolylmethane, for treating and/or preventing neurological disorders
US12251472B1 (en) 2024-05-20 2025-03-18 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
US12251468B1 (en) 2024-05-20 2025-03-18 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
US12246092B1 (en) 2024-05-20 2025-03-11 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
CN119280103B (zh) * 2024-10-16 2025-09-02 北京青颜博识健康管理有限公司 一种含有胶原蛋白的微胶囊乳液及其制备方法
WO2026085231A1 (en) 2024-10-16 2026-04-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Integrase strand transfer inhibitors

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB929402A (en) * 1958-12-22 1963-06-19 Upjohn Co Encapsulated emulsions and processes for their preparation
US3092553A (en) * 1959-01-30 1963-06-04 Jr Carl E Fisher Pharmaceutical preparations and method and apparatus for making same
NL280825A (es) * 1962-07-11
GB1298194A (en) * 1968-11-20 1972-11-29 Agfa Gevaert Improved method for encapsulating aqueous or hydrophilic material, the capsules obtained therewith and their application
BE744162A (fr) * 1969-01-16 1970-06-15 Fuji Photo Film Co Ltd Procede d'encapsulage
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
BE759520A (fr) * 1969-11-28 1971-04-30 Aspro Nicholas Ltd Compositions d'aspirine
FR2236483B1 (es) * 1973-07-12 1976-11-12 Choay Sa
US4272398A (en) * 1978-08-17 1981-06-09 The United States Of America As Represented By The Secretary Of Agriculture Microencapsulation process
US4234571A (en) * 1979-06-11 1980-11-18 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide derivatives of luteinizing hormone releasing hormone
US4622244A (en) * 1979-09-04 1986-11-11 The Washington University Process for preparation of microcapsules
US4273920A (en) * 1979-09-12 1981-06-16 Eli Lilly And Company Polymerization process and product
US4389330A (en) * 1980-10-06 1983-06-21 Stolle Research And Development Corporation Microencapsulation process
US4675189A (en) * 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
PH19942A (en) * 1980-11-18 1986-08-14 Sintex Inc Microencapsulation of water soluble polypeptides
IE52535B1 (en) * 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4637905A (en) * 1982-03-04 1987-01-20 Batelle Development Corporation Process of preparing microcapsules of lactides or lactide copolymers with glycolides and/or ε-caprolactones
JPS60100516A (ja) * 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
US4555399A (en) * 1983-11-18 1985-11-26 Key Pharmaceuticals, Inc. Aspirin tablet
EP0190833B1 (en) * 1985-02-07 1991-03-27 Takeda Chemical Industries, Ltd. Method for producing microcapsule
JP2551756B2 (ja) * 1985-05-07 1996-11-06 武田薬品工業株式会社 ポリオキシカルボン酸エステルおよびその製造法
US4710384A (en) * 1986-07-28 1987-12-01 Avner Rotman Sustained release tablets made from microcapsules
US4971893A (en) * 1987-03-30 1990-11-20 E. I. Du Pont De Nemours And Company Element containing lower gloss protective covering and a pre-press color proof

Also Published As

Publication number Publication date
US5476663A (en) 1995-12-19
IE842830L (en) 1985-05-04
EP0145240B1 (en) 1989-04-19
HK3792A (en) 1992-01-17
BG60493B2 (bg) 1995-05-31
EP0145240A2 (en) 1985-06-19
US4917893A (en) 1990-04-17
US5631021A (en) 1997-05-20
GR80818B (en) 1985-03-04
HUT37037A (en) 1985-11-28
SG103491G (en) 1992-01-17
PT79450B (en) 1986-12-11
JPS60100516A (ja) 1985-06-04
CA1233414A (en) 1988-03-01
IE57721B1 (en) 1993-03-24
US4652441A (en) 1987-03-24
JPH0157087B2 (es) 1989-12-04
US4711782A (en) 1987-12-08
US5061492A (en) 1991-10-29
PT79450A (en) 1984-12-01
US5631020A (en) 1997-05-20
HU193910B (en) 1987-12-28
ES8605983A1 (es) 1986-04-01
EP0145240A3 (en) 1985-07-03
DE3477732D1 (en) 1989-05-24

Similar Documents

Publication Publication Date Title
ES523927A0 (es) Un metodo de fabricar un bizcocho
ES528620A0 (es) Un metodo de preparacion de una espuma de poliorganosiloxano.
ES516254A0 (es) "un metodo de producir derivados de 1-sulfo-2-oxoazetidina".
NO180499C (no) Fremgangsmåte for pakking av en brönn
PL272025A1 (en) Method for manufacturing derivatives of 10-dihydro-10-desketo-11-azaerythronolide a
AU2939589A (en) Method of constructing a well
PL265207A1 (en) A method of phenylepiperazine derivatives production
ES531557A0 (es) Un metodo de producir l-carnitina
ES528856A0 (es) Un metodo de construir una cubierta de neumatico
ES532509A0 (es) Un metodo de preparar dihidrobenzopirrolbenzodiazepinas
ES525882A0 (es) Un metodo de formar articulos afieltrados
ES537717A0 (es) Un metodo de fabricar 1, 4-dihidropiridina-3-carboxilatos
PL247440A1 (en) Method of obtaining a pharmacological agent
ES512832A0 (es) Un metodo de produccion de compuesto de dihidropiridina.
ES548109A0 (es) Un metodo de preparacion de n,n-di-n-propil-4-hidroxi-3- metanosulfonamido-fenetilamina
IT8167530A0 (it) Metodo di formatura a rotazione
ES540907A0 (es) Un metodo de producir una composicion farmaceutica estabili-zada
GB2133439B (en) Method of enlarging a tunnel
GB2134563B (en) Method of enlarging a tunnel
ES530184A0 (es) Metodo de producir una preparacion yodofora farmaceutica
ES533187A0 (es) Un metodo para la preparacion de derivados penem
ES518562A0 (es) Un metodo de producir un derivado de 4-ciano-2-azetidinona.
AU2236988A (en) Method of forming a tube
DE3265169D1 (en) A method of producing a pallet
ES537402A0 (es) Un metodo de preparar derivados de fluoreno

Legal Events

Date Code Title Description
FD1A Patent lapsed

Effective date: 20050924